These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 29315147

  • 1. Nonmelanoma Skin Cancer Risk in Patients With Inflammatory Bowel Disease Undergoing Thiopurine Therapy: A Systematic Review of the Literature.
    Hagen JW, Pugliano-Mauro MA.
    Dermatol Surg; 2018 Apr; 44(4):469-480. PubMed ID: 29315147
    [Abstract] [Full Text] [Related]

  • 2. The risk of non-melanoma skin cancer in New Zealand in inflammatory bowel disease patients treated with thiopurines.
    Bahi M, Walmsley RS, Gray AR, Young D, Hobbs CE, Aluzaite K, Schultz M.
    J Gastroenterol Hepatol; 2018 May; 33(5):1047-1052. PubMed ID: 29105142
    [Abstract] [Full Text] [Related]

  • 3. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis.
    Ariyaratnam J, Subramanian V.
    Am J Gastroenterol; 2014 Feb; 109(2):163-9. PubMed ID: 24419479
    [Abstract] [Full Text] [Related]

  • 4. Risk of skin cancers in thiopurines-treated and thiopurines-untreated patients with inflammatory bowel disease: A systematic review and meta-analysis.
    Huang SZ, Liu ZC, Liao WX, Wei JX, Huang XW, Yang C, Xia YH, Li L, Ye C, Dai SX.
    J Gastroenterol Hepatol; 2019 Mar; 34(3):507-516. PubMed ID: 30393891
    [Abstract] [Full Text] [Related]

  • 5. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.
    Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, Carbonnel F, Colombel JF, Dupas JL, Godeberge P, Hugot JP, Lémann M, Nahon S, Sabaté JM, Tucat G, Beaugerie L, Cesame Study Group.
    Gastroenterology; 2011 Nov; 141(5):1621-28.e1-5. PubMed ID: 21708105
    [Abstract] [Full Text] [Related]

  • 6. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease.
    Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD.
    Gastroenterology; 2012 Aug; 143(2):390-399.e1. PubMed ID: 22584081
    [Abstract] [Full Text] [Related]

  • 7. Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer.
    Scott FI, Mamtani R, Brensinger CM, Haynes K, Chiesa-Fuxench ZC, Zhang J, Chen L, Xie F, Yun H, Osterman MT, Beukelman T, Margolis DJ, Curtis JR, Lewis JD.
    JAMA Dermatol; 2016 Feb; 152(2):164-72. PubMed ID: 26510126
    [Abstract] [Full Text] [Related]

  • 8. Risks of Melanoma and Nonmelanoma Skin Cancers Pre- and Post-Inflammatory Bowel Disease Diagnosis.
    Narous M, Nugent Z, Singh H, Bernstein CN.
    Inflamm Bowel Dis; 2023 Jul 05; 29(7):1047-1056. PubMed ID: 35929649
    [Abstract] [Full Text] [Related]

  • 9. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
    Kotlyar DS, Lewis JD, Beaugerie L, Tierney A, Brensinger CM, Gisbert JP, Loftus EV, Peyrin-Biroulet L, Blonski WC, Van Domselaar M, Chaparro M, Sandilya S, Bewtra M, Beigel F, Biancone L, Lichtenstein GR.
    Clin Gastroenterol Hepatol; 2015 May 05; 13(5):847-58.e4; quiz e48-50. PubMed ID: 24879926
    [Abstract] [Full Text] [Related]

  • 10. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease.
    Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD.
    Clin Gastroenterol Hepatol; 2010 Mar 05; 8(3):268-74. PubMed ID: 20005977
    [Abstract] [Full Text] [Related]

  • 11. Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD.
    Amin J, Huang B, Yoon J, Shih DQ.
    Inflamm Bowel Dis; 2015 Feb 05; 21(2):445-52. PubMed ID: 25248004
    [Abstract] [Full Text] [Related]

  • 12. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts.
    Jharap B, Seinen ML, de Boer NK, van Ginkel JR, Linskens RK, Kneppelhout JC, Mulder CJ, van Bodegraven AA.
    Inflamm Bowel Dis; 2010 Sep 05; 16(9):1541-9. PubMed ID: 20155846
    [Abstract] [Full Text] [Related]

  • 13. Thiopurine use associated with reduced B and natural killer cells in inflammatory bowel disease.
    Lord JD, Shows DM.
    World J Gastroenterol; 2017 May 14; 23(18):3240-3251. PubMed ID: 28566883
    [Abstract] [Full Text] [Related]

  • 14. Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines.
    Dotan I, Werner L, Vigodman S, Agarwal S, Pfeffer J, Horowitz N, Malter L, Abreu M, Ullman T, Guzner-Gur H, Halpern Z, Mayer L.
    Inflamm Bowel Dis; 2012 Feb 14; 18(2):261-8. PubMed ID: 21438101
    [Abstract] [Full Text] [Related]

  • 15. Optimizing thiopurine therapy in inflammatory bowel disease.
    Chevaux JB, Peyrin-Biroulet L, Sparrow MP.
    Inflamm Bowel Dis; 2011 Jun 14; 17(6):1428-35. PubMed ID: 20949566
    [Abstract] [Full Text] [Related]

  • 16. Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain.
    Gómez-García M, Cabello-Tapia MJ, Sánchez-Capilla AD, De Teresa-Galván J, Redondo-Cerezo E.
    World J Gastroenterol; 2013 Aug 14; 19(30):4877-86. PubMed ID: 23946592
    [Abstract] [Full Text] [Related]

  • 17. Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis.
    Jess T, Lopez A, Andersson M, Beaugerie L, Peyrin-Biroulet L.
    Clin Gastroenterol Hepatol; 2014 Nov 14; 12(11):1793-1800.e1. PubMed ID: 24907505
    [Abstract] [Full Text] [Related]

  • 18. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study.
    Setshedi M, Epstein D, Winter TA, Myer L, Watermeyer G, Hift R.
    J Gastroenterol Hepatol; 2012 Feb 14; 27(2):385-9. PubMed ID: 21793904
    [Abstract] [Full Text] [Related]

  • 19. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease.
    Haines ML, Ajlouni Y, Irving PM, Sparrow MP, Rose R, Gearry RB, Gibson PR.
    Inflamm Bowel Dis; 2011 Jun 14; 17(6):1301-7. PubMed ID: 20812329
    [Abstract] [Full Text] [Related]

  • 20. Risk of melanoma and non-melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort.
    Abbas AM, Almukhtar RM, Loftus EV, Lichtenstein GR, Khan N.
    Am J Gastroenterol; 2014 Nov 14; 109(11):1781-93. PubMed ID: 25244964
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.